GSK-3β Inhibitor (Topical)
Androgenetic Alopecia
Phase IIActive (via Cassiopea)
Key Facts
Indication
Androgenetic Alopecia
Phase
Phase II
Status
Active (via Cassiopea)
Company
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.
View full company profileTherapeutic Areas
Other Androgenetic Alopecia Drugs
| Drug | Company | Phase |
|---|---|---|
| TOP-M119 | Topadur Pharma | Phase 2 |
| AMP-303 | Amplifica | Phase 1 |
| GM-502 | Galderma Group | Phase 2 |